PSTX Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Poseida Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.81 |
| 52 Week High | US$4.27 |
| 52 Week Low | US$1.83 |
| Beta | 0.52 |
| 11 Month Change | -28.86% |
| 3 Month Change | -2.43% |
| 1 Year Change | 27.15% |
| 33 Year Change | -67.48% |
| 5 Year Change | n/a |
| Change since IPO | -81.69% |
Recent News & Updates
Recent updates
Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop
Aug 28
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%
Apr 09Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Mar 17Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)
Aug 13Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding
Apr 17Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech
Sep 04Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Aug 11Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B
Aug 03Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
May 15Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
Oct 30What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?
Mar 19Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?
Jan 25Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 09FDA lifts clinical hold on Poseida's prostate cancer cell therapy study
Nov 02Shareholder Returns
| PSTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.6% | 0.4% | 0.6% |
| 1Y | 27.1% | 14.0% | 22.9% |
Return vs Industry: PSTX exceeded the US Biotechs industry which returned 15.8% over the past year.
Return vs Market: PSTX exceeded the US Market which returned 24.9% over the past year.
Price Volatility
| PSTX volatility | |
|---|---|
| PSTX Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PSTX's share price has been volatile over the past 3 months.
Volatility Over Time: PSTX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 337 | Kristin Yarema | poseida.com |
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC.
Poseida Therapeutics, Inc. Fundamentals Summary
| PSTX fundamental statistics | |
|---|---|
| Market cap | US$297.19m |
| Earnings (TTM) | -US$112.77m |
| Revenue (TTM) | US$88.46m |
3.1x
P/S Ratio-2.4x
P/E RatioIs PSTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSTX income statement (TTM) | |
|---|---|
| Revenue | US$88.46m |
| Cost of Revenue | US$156.78m |
| Gross Profit | -US$68.32m |
| Other Expenses | US$44.46m |
| Earnings | -US$112.77m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | -77.23% |
| Net Profit Margin | -127.48% |
| Debt/Equity Ratio | 96.7% |
How did PSTX perform over the long term?
See historical performance and comparison